|
|
EFSA News in brief, 9 February 2015
The guidance, which was first published in 2011, is intended to assist applicants in preparing their applications for the authorisation of health claims related to the gastrointestinal tract, the immune system, and defence against pathogenic microorganisms. It includes examples from past and ongoing evaluations to illustrate EFSA’s approach to evaluating health relationships and outcome variables which may be acceptable in these areas, as well as the conditions under which they may be acceptable.
The revision takes into account the outcome of a public consultation on a discussion paper together with new scientific evidence available to EFSA’s Panel on Dietetic Products, Nutrition and Allergies (NDA) and the experience gained from the evaluation of health claim applications related to the gastrointestinal tract, the immune system, and defence against pathogenic microorganisms.
Interested parties are invited to submit written comments by 23 March 2015.
For further details, see: